UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Real-world effectiveness and tolerability of small-cell lung cancer (SCLC) treatments: A systematic literature review (SLR)

PloS one, 2019-07, Vol.14 (7), p.e0219622

2019

Volltextzugriff (PDF)

Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis

Lung cancer (Amsterdam, Netherlands), 2020-02, Vol.140, p.99-106

2020

Volltextzugriff (PDF)

Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis

The lancet oncology, 2019-10, Vol.20 (10), p.1395-1408

2019

Volltextzugriff (PDF)

Impact of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non–Small Cell Lung Cancer: Results from the CheckMate 017 Study

Journal of thoracic oncology, 2018-02, Vol.13 (2), p.194-204

2018

Volltextzugriff (PDF)

Real-world effectiveness of immunotherapies in pre-treated, advanced non-small cell lung cancer Patients: A systematic literature review

Lung cancer (Amsterdam, Netherlands), 2022-04, Vol.166, p.205-220

2022

Volltextzugriff (PDF)

Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057

European journal of cancer (1990), 2018-10, Vol.102, p.23-30

2018

Volltextzugriff (PDF)

Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis

BMC cancer, 2022-03, Vol.22 (1), p.255-255, Article 255

2022

Volltextzugriff (PDF)

Treatment patterns and outcomes for patients with malignant pleural mesothelioma in England in 2013–2017: A nationwide CAS registry analysis from the I-O Optimise initiative

Lung cancer (Amsterdam, Netherlands), 2021-12, Vol.162, p.185-193

2021

Volltextzugriff (PDF)

Correlations between objective response rate and survival-based endpoints in first-line advanced non-small cell lung Cancer: A systematic review and meta-analysis

Lung cancer (Amsterdam, Netherlands), 2022-08, Vol.170, p.122-132

2022

Volltextzugriff (PDF)

Real-World Relationship of Early End Points to Survival End Points in Patients with Resectable Non-Small-Cell Lung Cancer

Future oncology (London, England), 2023-08, Vol.19 (26), p.1785-1801

2023

Volltextzugriff (PDF)

Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature review and network meta-analysis

Lung cancer (Amsterdam, Netherlands), 2023-03, Vol.177, p.11-20

2023

Volltextzugriff (PDF)

Caring for relatives with lung cancer in Europe: an evaluation of caregivers' experience

Quality of life research, 2015-12, Vol.24 (12), p.2843-2852

2015

Volltextzugriff (PDF)

How cancer patients value hope and the implications for cost-effectiveness assessments of high-cost cancer therapies

Health Affairs, 2012-04, Vol.31 (4), p.676-682

2012

Volltextzugriff (PDF)

Cost-effectiveness of nivolumab in patients with NSCLC in the United States

The American journal of managed care, 2021-08, Vol.27 (8), p.e254-e260

2021

Volltextzugriff (PDF)

Algorithms to identify radiotherapy intent in unresected non-metastatic non-small-cell lung cancer: an I-O Optimise analysis

Future oncology (London, England), 2024-06, p.1

2024

Volltextzugriff (PDF)

Modelling Health State Utilities as a Transformation of Time to Death in Patients with Non-Small Cell Lung Cancer

PharmacoEconomics, 2024-01, Vol.42 (1), p.109-116

2024

Volltextzugriff (PDF)

Effects of home-based pulmonary rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial

Annals of internal medicine, 2008-12, Vol.149 (12), p.869

2008

Volltextzugriff (PDF)

An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?

Health policy (Amsterdam), 2018-06, Vol.122 (6), p.607-613

2018

Volltextzugriff (PDF)

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes

European journal of cancer (1990), 2023-04, Vol.183, p.174-187

2023

Volltextzugriff (PDF)

Treatment patterns and survival outcomes for patients with non-small cell lung cancer in the UK in the preimmunology era: a REAL-Oncology database analysis from the I-O Optimise initiative

BMJ open, 2021-09, Vol.11 (9), p.e046396-e046396

2021

Volltextzugriff (PDF)

Real-World Clinical Impact of Immune Checkpoint Inhibitors in Patients With Advanced/Metastatic Non–Small Cell Lung Cancer After Platinum Chemotherapy

Clinical lung cancer, 2019-07, Vol.20 (4), p.287-296.e4

2019

Volltextzugriff (PDF)

Evolution of treatment patterns and survival outcomes in patients with advanced non-small cell lung cancer treated at Frankfurt University Hospital in 2012-2018

BMC pulmonary medicine, 2023-01, Vol.23 (1), p.16-16, Article 16

2023

Volltextzugriff (PDF)

Treatment-Switching Adjustment of Overall Survival in CheckMate 227 Part 1 Evaluating First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy for Metastatic Nonsmall Cell Lung Cancer

Clinical lung cancer, 2024-06

2024

Volltextzugriff (PDF)

1 – 25 von 161

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(133)
Mit Volltextzugriff
(118)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Real-world effectiveness and tolerability of small-cell lung cancer (SCLC) treatments: A systematic literature review (SLR)

Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis

Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial

Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis

Impact of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non–Small Cell Lung Cancer: Results from the CheckMate 017 Study

Real-world effectiveness of immunotherapies in pre-treated, advanced non-small cell lung cancer Patients: A systematic literature review

Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057

Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis

Treatment patterns and outcomes for patients with malignant pleural mesothelioma in England in 2013–2017: A nationwide CAS registry analysis from the I-O Optimise initiative

Correlations between objective response rate and survival-based endpoints in first-line advanced non-small cell lung Cancer: A systematic review and meta-analysis

Real-World Relationship of Early End Points to Survival End Points in Patients with Resectable Non-Small-Cell Lung Cancer

Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature review and network meta-analysis

Caring for relatives with lung cancer in Europe: an evaluation of caregivers' experience

How cancer patients value hope and the implications for cost-effectiveness assessments of high-cost cancer therapies

Cost-effectiveness of nivolumab in patients with NSCLC in the United States

Algorithms to identify radiotherapy intent in unresected non-metastatic non-small-cell lung cancer: an I-O Optimise analysis

Modelling Health State Utilities as a Transformation of Time to Death in Patients with Non-Small Cell Lung Cancer

Effects of home-based pulmonary rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial

An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes

Treatment patterns and survival outcomes for patients with non-small cell lung cancer in the UK in the preimmunology era: a REAL-Oncology database analysis from the I-O Optimise initiative

First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1

Real-World Clinical Impact of Immune Checkpoint Inhibitors in Patients With Advanced/Metastatic Non–Small Cell Lung Cancer After Platinum Chemotherapy

Evolution of treatment patterns and survival outcomes in patients with advanced non-small cell lung cancer treated at Frankfurt University Hospital in 2012-2018

Treatment-Switching Adjustment of Overall Survival in CheckMate 227 Part 1 Evaluating First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy for Metastatic Nonsmall Cell Lung Cancer

Suchergebnisse filtern